Last reviewed · How we verify
NCT04695223
Arsenic Trioxide for Structural p53 Mutations
Phase 2 trial testing Arsenic Trioxide in Arsenic Trioxide in 30 participants. Status unknown.
31 August 2021
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2021 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 October 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Arsenic Trioxide (ARSENIC TRIOXIDE) — full drug profile →
Conditions studied
- Arsenic Trioxide — all drugs for Arsenic Trioxide →
- p53 Mutations — all drugs for p53 Mutations →
- Refractory Cancer — all drugs for Refractory Cancer →
- Intractable Cancer — all drugs for Intractable Cancer →
Sponsor
Shanghai Changzheng Hospital
Who can join
Adults 18 to 80, any sex, with Arsenic Trioxide or p53 Mutations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting p53 pathways: mechanisms, structures, and advances in therapy.
Wang H, Guo M, Wei H, Chen Y. · · 2023 · cited 580× · PMID 36859359 · DOI 10.1038/s41392-023-01347-1 -
Drugging p53 in cancer: one protein, many targets.
Hassin O, Oren M. · · 2023 · cited 496× · PMID 36216888 · DOI 10.1038/s41573-022-00571-8 -
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X, Zhang T, Su W, Dou Z, et al · · 2022 · cited 304× · PMID 36400749 · DOI 10.1038/s41419-022-05408-1 -
The Function of the Mutant p53-R175H in Cancer.
Chiang YT, Chien YC, Lin YH, Wu HH, et al · · 2021 · cited 82× · PMID 34439241 · DOI 10.3390/cancers13164088 -
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S, Iwakuma T. · · 2023 · cited 77× · PMID 36672377 · DOI 10.3390/cancers15020429 -
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S. · · 2024 · cited 57× · PMID 38311377 · DOI 10.1002/cac2.12520 -
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).
Tornesello ML. · · 2025 · cited 40× · PMID 39450536 · DOI 10.3892/ijmm.2024.5448 -
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Duffy MJ, Tang M, Rajaram S, O'Grady S, et al · · 2022 · cited 36× · PMID 36139658 · DOI 10.3390/cancers14184499
Verify or expand the search:
- PubMed search for NCT04695223
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Arsenic Trioxide
Trials testing the same drug.
- NCT04793919 — Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia · Phase 2 · recruiting
- NCT03980665 — The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART · Phase 1 · unknown
- NCT05297123 — Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid · Phase 1 · unknown
- NCT03377725 — Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) · Phase 3 · withdrawn
- NCT03503864 — Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma · Phase 2 · active not recruiting
Other recruiting trials for Arsenic Trioxide
Currently open trials in the same condition.
- NCT05682131 — South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol · Phase 4 · recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04695223 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 6 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04695223.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing